Real-world Assessment, Prediction, and Treatment Unit.
Department of Psychiatry and Behavioral Sciences.
Exp Clin Psychopharmacol. 2022 Dec;30(6):983-996. doi: 10.1037/pha0000518. Epub 2021 Nov 4.
Kratom, a plant that produces opioid-like effects, has gained popularity in the U.S. for self-treating symptoms of chronic pain, mood disorders, and substance-use disorders (SUDs). Most data on kratom are from surveys into which current kratom-using adults could self-select; such surveys may underrepresent people who have used kratom and chosen to stop. Available data also do not adequately assess important psychosocial factors surrounding kratom use. In this study, U.S. adults who reported past 6-month alcohol, opioid, and/or stimulant use ( = 1,670) were recruited via Amazon Mechanical Turk between September and December 2020. Of the 1,510 evaluable respondents, 202 (13.4%) reported lifetime kratom use. Kratom-using adults, relative to others, were typically younger, male, unpartnered, without children, and had lower income. They had higher rates of chronic pain (31.7% vs. 21.9%, = .003), childhood adversity, anxiety, and depression ( < .001), and lower perceived social rank ( = .19, .02-.22) and socioeconomic status ( = .37 .16-.26). They also reported higher use rates for most substances (except alcohol); this included medically supervised and unsupervised use of prescription opioids and diverted opioid agonist therapy (OAT) medications. Most (83.2%) met diagnostic criteria for any past-year SUD. Those reporting kratom use were less likely to reside in an urban/suburban area. The strongest predictors of kratom use were use of other drugs: cannabidiol ( = 3.73), psychedelics ( = 3.39), and nonmedical prescription opioids ( = 1.72). Another strong predictor was lifetime OAT utilization ( = 2.31). Despite seemingly poorer psychosocial functioning and health among respondents reporting lifetime kratom use, use of other substances may be the strongest indicators of kratom use. (PsycInfo Database Record (c) 2022 APA, all rights reserved).
译文:植物 ****(** **Kratom ****)** **能产生类似阿片的效果 ****,** **已在美国流行起来 ****,** **用于自行治疗慢性疼痛 ****、** **情绪障碍和物质使用障碍(SUDs) **等症状 ****。** **关于 **Kratom **的大多数数据都来自于对当前使用 **Kratom **的成年人的调查 ****,** **其中可能存在自我选择的情况 ****;** **这样的调查可能会低估那些使用过 **Kratom **并选择停止使用的人 ****。** **现有的数据也不能充分评估与 **Kratom **使用相关的重要社会心理因素 ****。** **在这项研究中 ****,** **我们通过亚马逊 Mechanical Turk 在 2020 年 9 月至 12 月期间招募了报告过去 6 个月内有酒精 ****、** **阿片类药物和/或兴奋剂使用史的美国成年人(n = 1670) ****。** **在 1510 名可评估的受访者中 ****,** **有 202 名(13.4%)报告称曾终生使用过 **Kratom ****。** **与其他受访者相比 ****,** **Kratom 使用者通常更年轻 ****、** **男性 ****、** **未婚 ****、** **没有孩子 ****、** **收入较低 ****。** **他们有更高的慢性疼痛率(31.7%比 21.9%, =.003) ****、** **更高的童年逆境经历 ****、** **焦虑和抑郁发生率(<.001) ****,** **以及更低的感知社会地位( =.19,.02-.22)和社会经济地位( =.37.16-.26) ****。** **他们也报告了更高的大多数物质使用频率(除了酒精);这包括接受监督和未经监督的处方类阿片药物和转用类阿片激动剂治疗(OAT)药物的使用 ****。** **大多数(83.2%)符合任何过去一年 SUD 的诊断标准 ****。** **报告使用 **Kratom **的人更不可能居住在城市/郊区 ****。** **Kratom 使用的最强预测因素是其他药物的使用:大麻素( = 3.73)、迷幻剂( = 3.39)和非医疗处方类阿片类药物( = 1.72) ****。** **另一个强有力的预测因素是终生 OAT 的利用( = 2.31) ****。** **尽管报告终生使用 **Kratom **的受访者的社会心理功能和健康状况似乎较差 ****,** **但其他物质的使用可能是 Kratom **使用的最强指标 ****。** ****(** **PsycInfo Database Record(c)2022 APA,保留所有权利) ****。**